XML 49 R20.htm IDEA: XBRL DOCUMENT v3.25.4
Segment Information
12 Months Ended
Jun. 30, 2025
Segment Information [Abstract]  
SEGMENT INFORMATION
14.SEGMENT INFORMATION

 

After the BIOX deconsolidation, that took place in June 24, 2025 the Group is organized under a single operating segment, which is “science-based food ingredients”. Operating segments are defined as components of an enterprise for which separate financial information is regularly evaluated by the chief operating decision maker, who in the Group’s case is the Executive Team, in deciding how to allocate resources and assess performance. The Executive Team is composed of the Chief Executive Officer (“CEO”), the Chief Financial Officer (“CFO”) and the Chief Technology Officer (“CTO”).

Prior to the BIOX deconsolidation, the Executive Team evaluates the Group’s financial information and resources and assess the financial performance of these resources as follows:

 

Seed and integrated products

 

The seed and integrated products segment focuses mainly on the development and commercialization of seed technologies and products that increase yield per hectare, with a focus on the provision of seed technologies integrated with crop protection and crop nutrition products designed to control weeds, insects or diseases, to increase their quality characteristics, to improve nutritional value and other benefits. The segment focuses on the commercialization of integrated products that combine three complementary components biotechnological events, germplasm and seed treatments—in order to increase crop productivity and create value for customers. While each component can increase yield independently, through an integrated technology strategy the segment offers products that complement and integrate with each other to generate higher yields in crops.

 

Currently the segment generates revenue from ordinary activities through the sale of seeds, integrated product packs, royalties and licenses charged to third parties, among others.

 

Crop protection

 

The crop protection segment mainly includes the development, production and marketing of high-tech adjuvants and a full range of pest control molecules and biocontrol products. Adjuvants are used in mixtures to facilitate the application and effectiveness of active ingredients, such as insecticides, leading to better performance, reduced usage rates and lower residue levels Insecticides and fungicides are applied to control pests and significantly reduce disease during the germination period.

 

The segment currently generates revenue from ordinary activities through the sale of adjuvants, insecticides, fungicides, and baits, among others.

 

Crop nutrition

 

The crop nutrition segment focuses mainly on the development, production and commercialization of inoculants that allow the biological fixation of nitrogen in the crops, and of fertilizers including biofertilizers and microgranulated fertilizers that optimize the productivity and yield of the crops.

 

Currently the segment generates income from ordinary activities through the sale of inoculants, bio-inductors, biological fertilizers and microgranulated fertilizers, among others.

 

The measurement principles for the Group’s segment reporting structure are based on the IFRS principles adopted in the Consolidated financial statements. Revenue generated by products and services exchanged between segments and entities within the Group are calculated based on market prices.

 

Emerging solutions

 

The emerging solution segment is based on providing R&D services, biotechnology capabilities and specialised expertise to facilitate the integration of technologies and product development efforts within the Group, as well as R&D services to third parties.

This segment includes revenue sources primarily related to agro-industrial biotechnology businesses, such as those generated by the production and commercialization of industrial enzymes and fermentation technology to convert sugars and oils into high-value molecules or compounds.

 

The measurement principles for the Group’s segment reporting structure are based on the IFRS principles adopted in the Consolidated financial statements. Revenue generated by products and services exchanged between segments and entities within the Group are calculated based on market prices.

 

The following tables present information with respect to the Group’s reporting segments:

 

 

Year ended June 30, 2025

  Seed and integrated products   Crop protection   Crop nutrition   Emerging solutions   Consolidated 
Revenues from contracts with customers                    
Sale of goods and services   60,535,026    181,908,584    76,054,689    267,261    318,765,560 
Royalties   1,414,864    
-
    
-
    
-
    1,414,864 
Right of use licenses   
-
    
-
    13,430,824    
-
    13,430,824 
Others                         
Initial recognition and changes in the fair value of biological assets at the point of harvest   1,764,863    
-
    
-
    
-
    1,764,863 
Government grants   
-
    
-
    
-
    3,412    3,412 
Total revenues   63,714,753    181,908,584    89,485,513    270,673    335,379,523 
                          
Cost of sales   (44,727,989)   (111,888,640)   (46,808,243)   
-
    (203,424,872)
Gross profit per segment   18,986,764    70,019,944    42,677,270    270,673    131,954,651 
% Gross margin   30%   38%   48%   100%   39%

 

Year ended June 30, 2024  Seed and integrated products   Crop protection   Crop nutrition   Emerging solutions   Consolidated 
Revenues from contracts with customers                    
Sale of goods and services   94,457,404    223,538,317    125,558,380    1,547,782    445,101,883 
Royalties   986,602    
-
    
-
    
-
    986,602 
Right of use licenses   1,000,000    
-
    19,287,845    
-
    20,287,845 
Others                         
Initial recognition and changes in the fair value of biological assets at the point of harvest   (45,746)   
-
    
-
    
-
    (45,746)
Government grants   
-
    
-
    
-
    197,519    197,519 
Total revenues   96,398,260    223,538,317    144,846,225    1,745,301    466,528,103 
                          
Cost of sales   (66,306,974)   (143,807,301)   (68,107,537)   (1,146,516)   (279,368,328)
Gross profit per segment   30,091,286    79,731,016    76,738,688    598,785    187,159,775 
% Gross margin   31%   36%   53%   34%   40%

 

Year ended June 30, 2023  Seed and integrated products   Crop protection   Crop nutrition   Emerging solutions   Consolidated 
Revenues from contracts with customers                    
Sale of goods and services   55,360,397    205,685,451    157,153,024    1,420,990    419,619,862 
Royalties   1,247,567    
-
    
-
    
-
    1,247,567 
Others                         
Initial recognition and changes in the fair value of biological assets at the point of harvest   319,428    153,460    137,666    
-
    610,554 
Government grants   
-
    
-
    
-
    93,509    93,509 
Total revenues   56,927,392    205,838,911    157,290,690    1,514,499    421,571,492 
                          
Cost of sales   (31,012,687)   (137,529,299)   (66,915,067)   (7,019)   (235,464,072)
Gross profit per segment   25,914,705    68,309,612    90,375,623    1,507,480    186,107,420 
% Gross margin   46%   33%   57%   100%   44%
  06/30/2025   06/30/2024   06/30/2023 
Revenue by similar group of products or services            
Seed and integrated products   61,949,890    96,444,006    56,607,954 
Seed Treatments Packs   28,476,396    29,992,052    32,563,161 
Seed & Royalties Payments & HB4 Program   33,473,494    66,451,954    24,044,803 
                
Crop protection   181,908,584    223,538,317    205,685,451 
Adjuvants   56,028,937    56,634,128    52,825,245 
Seed CP Products and Services   28,890,840    34,877,911    26,080,587 
Other CP Products and Services   62,983,430    103,092,454    94,277,444 
Bioprotection   34,005,377    28,933,824    32,502,175 
                
Crop nutrition   89,485,513    144,846,225    157,153,024 
Inoculants & Biofertilizers   22,445,093    18,315,253    23,621,534 
Micro-beaded Fertilizers   56,461,771    91,786,942    90,827,714 
Biostimulants   10,578,649    15,456,185    9,800,318 
Syngenta up-front fee   
-
    19,287,845    32,903,458 
                
Emerging solutions   270,673    1,745,301    1,514,499 
Management expenses   267,261    1,547,782    1,420,990 
Government grants   3,412    197,519    93,509 
                
Total revenues   333,614,660    466,573,849    420,960,938 

 

As of the current period, geographical information is reported by main countries and regions. LATAM refers to Latin America countries, excluding Argentina and Brazil which are reported separately. North America includes United States of America and Canada. The EMEA region covers Europe, the Middle East and Africa. The Group has recast the comparative figures accordingly.

 

Geographical information

 

   06/30/2025   06/30/2024   06/30/2023 
             
Argentina   231,823,079    348,366,339    289,346,766 
Brazil   17,673,809    24,175,116    23,690,028 
LATAM   23,900,621    21,952,339    21,044,547 
North America   30,107,865    27,543,558    30,768,912 
EMEA   7,920,550    21,320,535    22,014,855 
Rest of the world   22,188,736    23,215,962    34,095,830 
Total revenues   333,614,660    466,573,849    420,960,938 
   06/30/2025   06/30/2024 
Non-current assets        
Argentina   12,493,920    139,722,896 
Brazil   
-
    7,698,175 
LATAM   
-
    1,162,654 
North America   53,447,180    189,199,549 
EMEA   12,662,860    44,141 
Rest of the world   
-
    26,279,731 
Total   78,603,960    364,107,146 
           
Property, plant and equipment   3,345,170    74,612,434 
Intangible assets   75,258,790    177,331,280 
Goodwill   
-
    112,163,432 
Total reportable assets   78,603,960    364,107,146 
Total non-reportable assets   126,105,586    585,729,699 
Total assets   204,709,546    949,836,845 

 

Following the Business Combination and the BIOX deconsolidation, the Executive team will evaluate the Group’s financial information and resources and assess the financial performance of these resources on a consolidated basis on the basis of Net revenue/loss for the period.